Q2 2025 Lifecore Biomedical Inc Earnings Call Transcript
| LFCR Stock | 6.14 0.29 4.51% |
Slightly above 62% of Lifecore Biomedical's investor base is looking to short. The analysis of the overall investor sentiment regarding Lifecore Biomedical suggests that many traders are alarmed. Lifecore Biomedical's investing sentiment overview a quick insight into current market opportunities from investing in Lifecore Biomedical. Many technical investors use Lifecore Biomedical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Lifecore |
Jan 02, 2025 0930PM GMTOperator Good afternoon, and thank you for joining Lifecores financial 2025 second-quarter earnings call. Now
Read at gurufocus.com
 |
Lifecore Biomedical Fundamental Analysis
We analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Lifecore Biomedical is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Lifecore Biomedical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lifecore Biomedical stock to make a market-neutral strategy. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics with similar companies.
Peers
Lifecore Biomedical Related Equities
| KMDA | Kamada | 6.36 | ||||
| DERM | Journey Medical | 4.62 | ||||
| AKAN | Akanda Corp | 3.77 | ||||
| IRWD | Ironwood Pharmaceuticals | 1.85 | ||||
| TLRY | Tilray | 3.42 | ||||
| CPIX | Cumberland Pharmaceuticals | 4.58 | ||||
| SHPH | Shuttle Pharmaceuticals | 6.12 |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.